Becton Dickinson and Co
Atvērts
SektorsVeselības aprūpe
145.69 -0.29
Pārskats
Akcijas cenas izmaiņa
24h
Min
145.38
Max
147.62
Ienākumi | -692M -310M |
|---|---|
Pārdošana | -538M 4.7B |
P/E Sektora vidējais | 26.176 49.052 |
EPS | 2.9 |
Dividenžu ienesīgums | 2.77 |
Peļņas marža | -6.576 |
Darbinieki | 60,000 |
EBITDA | -1B 189M |
Rekomendācijas | Pirkt |
|---|---|
Prognoze 12 mēnešiem | +21.24% upside |
Dividenžu ienesīgums Sektora vidējais | 2.77% 2.36% |
|---|---|
Nākamie ieņēmumi | 2026. g. 6. aug. |
Nākamais dividenžu datums | 2026. g. 30. jūn. |
Tirgus kapitalizācija | -292M 41B |
|---|---|
Iepriekšējā atvēršanas cena | 145.98 |
Iepriekšējā slēgšanas cena | 145.69 |
Ziņu noskaņojums
By Acuity
66%
34%
300 / 342 Rangs Healthcare
Becton Dickinson and Co Grafiks
Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.
Par Becton Dickinson and Co
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.